Suven pharmaceuticals - Latest News Update, Information, Photos & Videos on Suven pharmaceuticals at Lokmat Times

Advent International on Monday said it has entered into a definitive agreement to acquire a significant stake in Suven Pharmaceuticals from the Jasti family, subject to regulatory approvals and conditions. However, the company didn't ascertain the amount of the deal.As part of the transaction, Advent said it would also be making an open offer to acquire an additional 26 per cent of the outstanding equity shares of the company from the public shareholders.When the acquisition completes, Advent intends to explore the merger of its portfolio company, Cohance Lifesciences with Suven, to build a contract development and manufacturing organisation (CDMO) and merchant active pharmaceutical ingredient (API) player servicing the pharma and speciality chemical markets, according to a statement shared by Suven with exchanges.The merger will be evaluated by the board taking into consideration the strategic rationale and accretiveness to Suven's public shareholders and will be subject to regulatory approvals and other customary approvals."We are delighted to bring Advent into Suven Pharma as a strategic investor. We have built a business with industry-leading growth and margins...Their experience and resources will launch the next phase of growth for Suven pharma. This move will benefit Suven platform immensely. The proposed collaboration with Cohance is a win-win for Suven and its public shareholders," said Venkateswarlu Jasti, Managing Director, Suven Pharmaceuticals.Suven Pharma, which was demerged from its parent entity, Suven Life Sciences, in 2020, is one of the leaders in the India pharma CDMO space with high growth and profitability, according to the Advent statement."We intend to explore a merger of Cohance with Suven in a manner which is synergistic and accretive for Suven's shareholders," said Shweta Jalan, Managing Partner and Head of Advent International in India.Suven Pharma, which was demerged from its parent entity, Suven Life Sciences, in 2020, is one of the leaders in the India pharma CDMO space with high growth and profitability.( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Pahalgam Terror Attack

Tahawwur Rana

IPL 2025

CM Devendra Fadnavis

Mumbai Local

Weather Update

Suven PharmaceuticalsFOLLOW

Suven pharmaceuticals, Latest News

Business :Cyril Amarchand Mangaldas advises sellers on Rs 9,500 Crore acquisition by Advent

Cyril Amarchand Mangaldas advised the promoters of Suven Pharmaceuticals Limited (Suven Pharmaceuticals) in relation to the acquisition of Suven Pharmaceuticals by global private equity firm Advent, for an aggregate amount of Rs 9,500 crore (approx.) ...

Business :Advent International to buy 'significant' stake in Suven Pharmaceuticals

Advent International on Monday said it has entered into a definitive agreement to acquire a significant stake in Suven ... ...